Accessibility Menu

Eikon Therapeutics

(NASDAQ) EIKN

Current Price$11.41
Market Cap$533.27M
Since IPO (2026)-24%
5 YearN/A
1 YearN/A
1 Month+10%

Eikon Therapeutics Financials at a Glance

Market Cap

$533.27M

Revenue (TTM)

$0.00

Net Income (TTM)

-$295.78

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.90 (High)

Price

$11.41

Volume

3,172,877.521

Open

$9.84

Previous Close

$11.45

Daily Range

$9.84 - $11.68

52-Week Range

$7.90 - $18.00

Estimated Earnings Date

Aug 10, 2026

EIKN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eikon Therapeutics

Industry

Biotechnology

Sector

Health Care

CEO

Roger M. Perlmutter, MD, PhD

Website

www.eikontx.com

Headquarters

Millbrae, CA 94030, US

EIKN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

43.07%

Return on Capital

N/A

Return on Assets

-19.11%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$533.27M

Shares Outstanding

54.14M

Volume

3.17M

Avg. Volume

304.28K

Financials (TTM)

Gross Profit

-$10.22M

Operating Income

-$170.51M

EBITDA

-$152.40M

Operating Cash Flow

-$131.53M

Capital Expenditure

-$328.00K

Free Cash Flow

-$131.85M

Cash & ST Invst.

$512.58M

Total Debt

$254.83M

Eikon Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$5.11M

N/A

Gross Margin

0.00%

N/A

Market Cap

$533.27M

N/A

Market Cap/Employee

$1.10M

N/A

Employees

484

N/A

Net Income

-$82.96M

N/A

EBITDA

-$77.85M

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$512.58M

N/A

Total Debt

$254.83M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$245.09M

N/A

Short Term Debt

$9.74M

N/A

Return on Assets

-19.11%

N/A

Return on Invested Capital

-21.16%

N/A

Free Cash Flow

-$90.06M

N/A

Operating Cash Flow

-$89.80M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,355.91-0.00%
^DJIDJI
$51,900.31-0.00%
^IXICNASDAQ
$25,303.49-0.00%
BTCBitcoin
$59,961.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$153.23+0.00%
KEELKeel Infrastructure
$6.03+0.03%
SOFISoFi Technologies
$17.88+0.03%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.67+0.04%

Questions About EIKN

What is the current price of Eikon Therapeutics?

Eikon Therapeutics is trading at $11.45 per share.

What is the 52-week range for Eikon Therapeutics?

Over the past 52 weeks, Eikon Therapeutics has traded between $7.90 and $18.00.

How much debt does Eikon Therapeutics have?

As of the most recent reporting period, Eikon Therapeutics reported total debt of $254.83M.

How much cash does Eikon Therapeutics have on hand?

Eikon Therapeutics reported $161.55M in cash and cash equivalents in its most recent financial results.

What is Eikon Therapeutics’s dividend yield?

Eikon Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services